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Harry Goldblatt and the discovery of renin
 
In 1934, pathologist Harry Goldblatt established the first animal model of 
hypertension. This model provided researchers with the tools to delineate the 
renin-angiotensin system of blood pressure control and, eventually, to design 
enzyme inhibitors for the treatment of chronic hypertension.
 
As early as the mid–19th century, physi-
cians had noted that patients with kidney
disease and those with long-term high
blood pressure (hypertension) both had
enlarged heart muscles. The first clue to
this kidney–hypertension connection
came from physiologists Robert Tiger-
stedt and Per Bergman who injected kid-
ney extracts into rabbits, thus triggering a
dramatic rise in blood pressure. In a pro-
phetic explanation, they suggested that
the kidneys produced a soluble protein—
they called it renin—that triggered a rise
in blood pressure (1).
 
A little help from man’s best friend
 
Decades later, the duo’s results prompted
attempts to provoke hypertension by
stressing or injuring the kidneys of ani-
mals. None were successful until Harry
Goldblatt arrived on the scene. Gold-
blatt had noted a characteristic narrow-
ing of the renal blood vessels in patients
who had died of hypertension. He rea-
soned that a decreased blood flow,
and thus oxygen supply, to the kid-
neys (ischemia) might somehow trig-
ger hypertension.
To test this idea, Goldblatt partially
constricted the major renal arteries of
dogs using a self-styled adjustable silver
clamp. Partial constriction of both renal
arteries resulted in a reproducible and
persistent rise in blood pressure, in the
absence of overt renal failure. Clamping
other large arteries—splenic or femoral—
had no effect, indicating that hyperten-
sion resulted specifically from kidney is-
chemia. Goldblatt published these results
in 1934 in the 
 
Journal of Experimental
Medicine
 
 (2).
Goldblatt’s explanation for his results
was similar to that of Tigerstedt and
Bergman: ischemia causes the kidneys to
produce an “internal secretion” that trig-
gers vasoconstriction. This idea met with
considerable skepticism. “Goldblatt’s
discovery was spectacular, but nobody
believed it,” recalls cardiologist John
Laragh. The skepticism, Laragh says, was
largely because of the technical difficulty
of Goldblatt’s procedure, which few
could reproduce. Eventually, Goldblatt’s
results were confirmed, but determining
the identity of the “internal secretion”
and renin (one and the same) took many
more years.
 
The hunt for renin
 
Two groups—one lead by Eduardo
Braun-Menendez and the other by Irvine
Page—attempted to purify renin but
found that the higher the purity of the
extract the less hypertensive activity it
had. This confusing result was eventually
explained by the discovery, in 1939, that
the pressure-raising substance was not
renin itself. Rather, renin was a pro-
teolytic enzyme that converted a plasma
peptide into a hypertensive product. Pu-
rifying renin away from its substrate had
abolished its activity.
The two groups christened the active
peptide product of renin “hypertensin”
Harry Goldblatt, 1964. Image provided by the 
National Library of Medicine.
 
and “angiotonin,” respectively (3, 4).
They later compromised and renamed it
“angiotensin” and its precursor “angio-
tensinogen” (5). Leonard Skeggs and
colleagues later discovered that there
were two forms of angiotensin (6), and it
is now known that renin initiates an en-
zymatic cascade in which angiotensino-
gen is converted into angiotensin I,
which is then processed by angiotensin-
converting enzyme (ACE) into angio-
tensin II. Angiotensin II is the true cul-
prit of hypertension.
 
Renin in human hypertension
 
Simple theory would predict high renin
levels in patients with hypertension, but
instead, says Laragh, “renin levels are all
over the place.” Thus, despite an under-
standing of the renin-angiotensin system
in animals, there was still doubt about its
role in humans. The development of
ACE inhibitors helped explain this
seeming inconsistency. Laragh and col-
leagues injected the first such inhibitor
into patients and found a drop in blood
pressure, but only in patients with high
levels of circulating renin (7). In other
studies, Laragh showed that hyperten-
sion not caused by increased renin results
from insufficient salt excretion by the
kidney (8). The work of Laragh and
others thus revealed that hypertension is
not a single mechanistic process, but still
confirmed Goldblatt’s original idea: pro-
duction of renin by the kidney regulates
blood pressure.
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